Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

SciClone Pharmaceuticals IPO Valuation: Not Pleasing

Cheerwin Group IPO: Doing Its Best to Innovate, Diversify and Grow in a Mature Market

Cheerwin IPO: Fairly Valued Compared to Recent IPOs in the Household, Personal and Pet Care Markets

Suzhou Basecare Medical IPO Valuation: Attractive Even at the Upper End of the IPO Pricing

New Horizon Health IPO Valuation: Healthy Valuation

Freee: Our 2021 Conviction Pick Grew 50% in 2QFY06/21 and That Should Continue

Joinn Laboratories IPO: Pioneer of Commercial GLP Laboratories in China Shows Promise

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Sciclone Pharmaceuticals / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/sciclone-pharmaceuticals-holdings-limited" target="_blank" data-smartkarma-citation="entities:17351:1" rel="noopener">Sciclone Pharmaceuticals (1863447D HK)</a> , a biopharmaceutical company with an integrated platform for product development and commercialisation has filed for an IPO on the Hong Kong Stock Exchange to raise about US$500m.The company focuses on oncology and severe infection as its key focus areas, two of the largest and fastest growing therapeutic areas in China. The company already has been generating revenues from the sale of its proprietary product Zadaxin, and at the same time, it also makes revenues from the sale of in-licensed products as well as from promotion products on behalf of its business partners in China.Though Zadaxin possesses the first mover advantage as the first branded thymalfasin drug in China, we remain concerned about the future prospects for Zadaxin if it is chosen for volume-based procurement catalog in China.

Sciclone Pharmaceuticals (1863447D HK) , a biopharmaceutical company with an integrated platform for product development and commercialisation has filed for an IPO on the Hong Kong Stock Exchange to raise about US$500m.The company focuses on oncology and severe infection as its key focus areas, two of the largest and fastest growing therapeutic areas in China. The company already has been generating revenues from the sale of its proprietary product Zadaxin, and at the same time, it also makes revenues from the sale of in-licensed products as well as from promotion products on behalf of its business partners in China.Though Zadaxin possesses the first mover advantage as the first branded thymalfasin drug in China, we remain concerned about the future prospects for Zadaxin if it is chosen for volume-based procurement catalog in China.

SciClone Pharmaceutical IPO: Future Prospects for Zadaxin Troubling